supportive therapies such as smoking cessation, and genetic and psychological counseling.
Since the discovery of AATD in the 1960s, knowledge and understanding of AAT and its deficiency have progressed significantly, although effective screening methods and non-intravenous therapy have remained elusive. The following is a comprehensive review of AATD primarily for physicians who treat COPD or asthma, highlighting advances into the epidemiology, screening, and treatment of AATD. These data are especially important for allergists because a third of AATD patients enter the healthcare system through allergists, and unfortunately, as noted in reference 9, this often delays the appropriate diagnosis and treatment. 8, 9 2 | GENETICS, SERUM AAT LEVELS, AND
EPIDE MIOLOGY
Individuals with AATD have a homo-or heterozygous mutation of the Serpina1 gene, 2 of which more than 150 alleles are recognized. 8 The most common allele (M, for "medium mobility" through an isoelectric gel) encodes normal AAT, with PI*MM the most common homozygous allele. The most common deficiency alleles are Z (slowest) and S (slower), which, in both cases, result from single amino acid substitutions. 2 The PI*Z allele accounts for 96% of known clinical cases of AATD, although the two most frequent deficiency alleles are thought to be PI*S (50%-60% of carriers) and PI*Z (10%-20% of carriers). 2, 10, 11 Rare null and dysfunctional alleles also exist, the former characterized by absent circulating AAT due to transcriptional or translational errors. 2 Lastly, the epigenetic silencing of Serpina1 has been reported which may explain the AATD effects in genetically unaffected individuals. 12 Different alleles are associated with different risks of developing lung and liver diseases (Table 1) . Despite PI*ZZ is the allele most associated with increased likelihood of developing COPD, PI*SZ and PI*MZ also show an increased risk, and data imply that disease progression in PI*SZ patients might be similar to Pi*ZZ. 2, 13 As shown in Table 1 , AAT concentrations vary according to genotype, with normal levels in the range of 20-53 μmol/L. 2, 4, 14, 15 Individuals with the PI*MM genotype have 105%-164% of normal levels, PI*MS 88%-137%, PI*SS 73%-106%, PI*MZ 66-100%, PI*SZ 49%-66%, while <15%-20% would suggest that an individual has the homozygous PI*ZZ, Z null, or null-null genotype. 4, 15, 16 While PI*Z and PI*S alleles are particularly prevalent in the north and south of Europe, respectively, deficiency alleles have been detected across diverse populations worldwide. 10, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] Another reason why AATD is highly under-diagnosed is that about 40% of individuals with PI deficiency alleles are asymptomatic for COPD. 1, 2, 28, 29 In CT lung scans, no clinically significant signs of emphysema were found in 14% of 119 patients with severe AATD. 30 Similarly, in the Swedish National Registry of AATD, no signs of COPD were evident in 30% of nonsmokers and 16% of smokers. 31 In a series of postmortems of individuals with AATD, no signs of COPD were found in 20% of cases. 31 In several studies, the rate of decline of FEV 1 in PI*ZZ patients was anywhere between 23 mL/y and 316 mL/y. [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] 52 In addition to the emphysematous symptoms of COPD, patients with AATD may also develop bronchiectasis, although it is unclear whether AATD causes bronchiectasis. In a case-control study of patients with a diagnosis of bronchiectasis with and without AATD, no association was found between AAT genes and bronchiectasis. 53 In another study of CT scans, clinically significant bronchiectasis was present in 27% of individuals with the PI*Z allele. 54 In accordance with these studies, the recommendation is to test for AATD whether the etiology of bronchiectasis remains unknown.
1,2
AATD-related COPD has traditionally been associated with more emphysematous damage to the lung bases. 2 However, emphysema is not always present. In a study of PI*ZZ patients, 20% had emphysema in radiographs 55 and, in another study using CT scans,
(A) (B)
F I G U R E 1 CT scans showing extensive emphysematous damage to the lungs. A, Axial plane of thorax; B, Coronal plane of thorax. CT, computed tomography. CT scans were kindly provided by Prof. Dr. Andreas Rembert Koczulla, Fachzentrum für Pneumologie Schön Klinik Berchtesgadener Land, Germany, and Klinik für Pneumologie, Marburg, Germany emphysema was present in 86% of PI*Z patients. 30 The latter study also demonstrated that a single physiologic parameter should not be used as a surrogate measure of disease severity. 30 In particular, basal emphysema was associated with greater impairment of FEV 1 , but less impairment of gas exchange and alveolar-arterial oxygen gradient versus apical distribution. 30 In the latter study, 36% of PI*Z patients with emphysema had apical damage. Notably, the traditional description of AATD-associated emphysema as predominantly basal and panacinar originates from limited autopsy studies and case series using chest radiographs, which has now been superseded by CT.
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| Extrapulmonary characteristics
Individuals with alleles associated with intrahepatocyte polymerization, such as Z, M malton , and S iiyama , are predisposed to liver disease, including hepatitis, cirrhosis, and hepatoma. 2, 56 In individuals with AATD, liver disease presents in a bimodal distribution, that is, neonatal hepatitis and cholestasis in infants and chronic liver disease in adults most of who are ZZ and usually over 50 years of age. 57 It is estimated that 10% of adults may develop symptomatic cirrhosis. In the first 20 years of life, about one-third of PI*ZZ carriers may develop liver disease, although most recover. 58, 59 In another study, based on 161 infants with liver dysfunction and use of isoelectric focusing, 15% had severe AATD and 12% moderate AATD. 60 Similarly, in a Swedish study, 18% of 120 newborns with PI*Z alleles AATD is also associated with various other conditions, including panniculitis (a skin condition that affects an estimated 1 per 1000 individuals with AATD) and granulomatosis with polyangiitis. [71] [72] [73] However, it is debatable whether this evidence will lead to widespread screening of newborns, as a diagnosis of AATD has been shown to increase stress in families. 71 Additional caveats include the lack of specific treatment for the AATD-associated liver disease, which is the primary cause of childhood morbidity, and the need for additional conclusive evidence that newborn screening ultimately results in better outcomes in longitudinal studies. 73 A pilot study of newborn screening for AATD recently commenced in New York State. suggests that patients on augmentation therapy with AAT may experience greater benefit when serum levels increase to well above 11 μmol/L, relative to patients with lower levels that were also above the protective threshold ( Figure 3) . 74, 80 Studies are presently being performed to reevaluate the protective threshold.
Either when serum AAT levels are found to be low or simultaneously when measuring AAT levels, additional diagnostic assessments can be used to identify AAT alleles and, therefore, strengthen the diagnosis of AATD. These assessments may include phenotyping by (A) (B) (C) However, the test is only designed to detect PI*Z alleles and additional testing is required to determine whether the patient is homoor heterozygous. 74 
| CURRENT TREATMENTS
As shown in Table 3 , a series of assessments, medications, and vaccinations should be considered for individuals with AATD, in addition to a healthy lifestyle that includes a good diet, exercise, and avoidance of stimuli of neutrophilic inflammation, including cigarette smoke, air pollution, and infections. 83, 84 Asthma should be treated aggressively. 85 Similarly, respiratory infections should be treated promptly and, as indicated by a study of completed questionnaires from 267 individuals with AAT, vaccinations against pneumococci (both protein conjugated and polysaccharide pneumococcal vaccines) and influenza should result in fewer exacerbations of lung disease. 47, 85 In addition, maintaining ideal body weight, limiting alcohol consumption and hepatitis A and B vaccine should be administered to prevent exacerbating already compromised liver disease from obesity-, toxicity-, and viral-induced hepatitis. Otherwise, inhaled therapy mimics the treatment of non-AATD COPD. As disease progresses, pulmonary rehabilitation and oxygen therapy may be essential. patients. 87 A recent UK study demonstrated improved quality of life postsurgery, with no difference in mortality when compared with controls. 88 In most cases, referral for a lung transplant is deferred until FEV 1 decrease to 30% or below.
With regard to liver transplantation, there are few reports of outcomes in patients with AATD. 89 Reviews of patient databases and case series suggest that AAT levels may normalize following liver transplantation in adults and children, although it is unclear whether this procedure has an impact on pulmonary outcomes. 90 Further research is required to assess the benefit-risk profile of liver, singlelung, and double-lung transplantation in patients with AATD and the need to augment patients' status postlung transplant. 69 Evidence for the use of augmentation therapy after lung transplantation is In general, lung volume reduction surgery (LVRS) is not recommended for patients with AATD. In a study of 10 patients with severe AATD, 2-year mortality was higher and exercise tolerance and FEV 1 were worse in patients randomized to LVRS versus medical treatment. 92 The recent ERS guidelines state that LVRS may be considered in selected patients with AATD, after careful appraisal of risks and benefits, but further studies are needed to confirm the role of such therapy. 69 
| Augmentation therapy
Intravenous augmentation therapy with infusions of purified AAT from pooled human plasma aims to raise and maintain serum AAT levels above the 11 μmol/L estimated protective threshold value. 2 Augmentation therapy is recommended only for patients who are below this protective threshold, that is, mainly those with the PI*ZZ genotype. 2 At present, augmentation therapy is the only approved medication that raises AAT levels both in the plasma and in the epithelial lining fluid (ELF), leading to a reduction in neutrophil elastase activity in the lungs. [93] [94] [95] Intravenous augmentation remains the only disease-specific therapy in AATD, and there is evidence that this slows decline in emphysema determined by CT density. 96 While the commercially available augmentation products (Prolastin, Zemaira/Respreeza, Glassia, and Aralast) have different purification processes and concentrations of AAT, there are only minor differences in storage, need for mixing, infusion rate, and cost, although there is a lack of comparative studies of the effectiveness of these products on lung parameters. 97, 98 Several recently completed or ongoing randomized clinical trials (including RAPID, EXACTLE, SPARK, and SPARTA) have increased our understanding of augmentation therapy with purified AAT preparations (Table 4) . These new studies benefited from the increased accuracy of CT to detect changes in lung density, relative to the previous gold standard of FEV 1 , which was used in studies in the 1990s. 82 Thus, the use of CT has overcome the impracticality of performing an adequately powered randomized placebo-controlled trial to assess the development of emphysema using FEV 1 , which changes slowly over time. In the EXACTLE randomized placebo-controlled trial in 77 patients with AATD, CT scans suggested that patients could benefit from treatment with AAT (Prolastin C; Grifols, Barcelona, Spain) 60 mg/kg weekly. 41 In the SPARK randomized crossover trial in 30 patients with AATD, more physiologic levels of serum AAT were gained following treatment with AAT (Prolastin C; Grifols) at a dose of 120 mg/kg weekly vs. 60 mg/kg. 102 Importantly, while AAT, α 1 -antitrypsin; AATD, α 1 -antitrypsin deficiency; COPD, chronic obstructive pulmonary disease; FEV 1 , forced expiratory volume in 1 s. Constructed using information from Henao and Craig, 124 Köhnlein et al, 47 O'Brien et al, 83 Alam et al, 84 and Sutherland and Cherniack. 85 CRAIG AND HENAO | 2115 improvements in lung function were not detected in the RAPID, EXACTLE, or SPARK trials (as the trials were not sufficiently powered to show this effect), augmentation therapy appears to be an effective treatment, which slows lung deterioration in patients with severe AATD and COPD, as noted by lung density measured by CT.
As a follow-up to SPARK, the ongoing SPARTA randomized placebocontrolled trial in 339 patients with AATD is comparing AAT (Prolastin C; Grifols) 120 mg/kg weekly and 60 mg/kg weekly, to assess both the change in 15th percentile lung density and the number of severe COPD exacerbations. 103 These recent randomized trials have added to less conclusive research from the 1990s and 1980s. In 1997, in a nonrandomized study of AAT 60 mg/kg weekly involving 295 patients, decline in FEV 1 was slower in treated versus untreated patients. 35 In 1999, the first randomized controlled trial of augmentation therapy performed with 56 patients; while no difference in FEV 1 was detected between the 250 mg/kg at 4-week intervals versus albumin, the decline in lung tissue was reduced in CT scans. 38 Since the late 1980s, several studies have demonstrated that 60 mg/kg AAT infused at weekly intervals maintained AAT levels above the protective threshold throughout the week in both plasma and ELF and, in the SPARK trial, 120 mg/kg weekly AAT was associated with increased serum AAT levels and was well tolerated. 102, [104] [105] [106] However, when administered at bi-weekly intervals in another study, the 120 mg/kg dose did not maintain AAT levels above the protective threshold. 107 At present, while augmentation therapy is only approved at doses of 60 mg/kg weekly in the United States, some clinicians prescribe higher doses when patients are not gaining adequate benefit (Figure 3 to be considered. At present, augmentation therapy is the only approved medication that effectively raises AAT levels both in serum and ELF. However, the costs of acquiring human plasma-derived AAT are high, and treatment costs of $60 000 to $150 000 per year (depending on body weight, pricing, and the costs of nursing care) exceed the standard criterion for cost-effectiveness of $50 000 per quality-adjusted life-year. 2, 117 Thus, more cost-effective treatment would be welcomed. With regard to efficacy, some studies indicate that the protective threshold of serum AAT (11 μmol/L, relative to 20-53 μmol/L in healthy individuals) may need to be revised. 27, 74, 80 The results of dose-ranging studies of augmentation therapy are eagerly awaited. 102 Similarly, while previous trials were not successful, further research into increasing the interval between infusions may result in appropriate efficacy, potentially with lower treatment costs.
A recent attempt to develop a guideline on management and treatment of AATD was published in 2016. 118 This publication was more of a consensus than a guideline, but is important reading for those that are managing patients with AATD, and agrees with previous recommendations with only a few outstanding exceptions. One exception is that while augmentation should be given to those AATD patients with FEV 1 ≤65%, treating at FEV 1 >65% should be decided upon on a case-by-case basis. In addition, augmentation therapy is recommended for individuals with necrotizing panniculitis. Importantly, the guideline also clarifies augmentation should not be offered to patients with the PI*MZ genotype.
In summary, several key issues should be borne in mind. AATD is highly under-recognized; less than 10% of cases are diagnosed. 
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